XML 125 R42.htm IDEA: XBRL DOCUMENT
v3.20.4

Segmentation of key figures (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Statement [line items] |
Segmentation - Consolidated income statements | Segmentation – consolidated income statements
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |
Net sales to third parties from continuing operations |  | 39 013 |  | 37 714 |  | 9 646 |  | 9 731 |  |  |  |  |  | 48 659 |  | 47 445 |
Sales to continuing and discontinued segments |  | 792 |  | 783 |  | 189 |  | 141 |  | – 981 |  | – 871 |  |  |  | 53 |
Net sales from continuing operations |  | 39 805 |  | 38 497 |  | 9 835 |  | 9 872 |  | – 981 |  | – 871 |  | 48 659 |  | 47 498 |
Other revenues |  | 1 018 |  | 1 092 |  | 53 |  | 63 |  | 168 |  | 24 |  | 1 239 |  | 1 179 |
Cost of goods sold |  | – 10 927 |  | – 10 050 |  | – 5 252 |  | – 5 334 |  | 1 058 |  | 959 |  | – 15 121 |  | – 14 425 |
Gross profit from continuing operations |  | 29 896 |  | 29 539 |  | 4 636 |  | 4 601 |  | 245 |  | 112 |  | 34 777 |  | 34 252 |
Selling, general and administration |  | – 11 657 |  | – 11 617 |  | – 2 076 |  | – 2 218 |  | – 464 |  | – 534 |  | – 14 197 |  | – 14 369 |
Research and development |  | – 8 118 |  | – 8 152 |  | – 862 |  | – 1 250 |  |  |  |  |  | – 8 980 |  | – 9 402 |
Other income |  | 922 |  | 1 586 |  | 176 |  | 167 |  | 644 |  | 278 |  | 1 742 |  | 2 031 |
Other expense |  | – 1 871 |  | – 2 069 |  | – 831 |  | – 749 |  | – 488 |  | – 608 |  | – 3 190 |  | – 3 426 |
Operating income from continuing operations |  | 9 172 |  | 9 287 |  | 1 043 |  | 551 |  | – 63 |  | – 752 |  | 10 152 |  | 9 086 |
Income from associated companies |  | 1 |  | 1 |  | 2 |  | 2 |  | 670 |  | 656 |  | 673 |  | 659 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | – 869 |  | – 850 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | – 78 |  | 45 |
Income before taxes from continuing operations |  |  |  |  |  |  |  |  |  |  |  |  |  | 9 878 |  | 8 940 |
Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | – 1 807 |  | – 1 793 |
Net income from continuing operations |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 071 |  | 7 147 |
Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | – 101 |
Gain on distribution of Alcon Inc. to Novartis AG shareholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 691 |
Net income from discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 590 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 071 |  | 11 737 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 072 |  | 11 732 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | – 1 |  | 5 |
Included in net income from continuing operations are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 91 |  | 245 |
Depreciation of property, plant and equipment |  | – 912 |  | – 952 |  | – 282 |  | – 283 |  | – 124 |  | – 110 |  | – 1 318 |  | – 1 345 |
Depreciation of right-of-use assets |  | – 273 |  | – 247 |  | – 41 |  | – 41 |  | – 16 |  | – 17 |  | – 330 |  | – 305 |
Amortization of intangible assets |  | – 3 080 |  | – 2 509 |  | – 370 |  | – 315 |  | – 12 |  | – 12 |  | – 3 462 |  | – 2 836 |
Impairment charges on property, plant and equipment, net |  | – 324 |  | – 100 |  | – 116 |  | – 101 |  |  |  | – 1 |  | – 440 |  | – 202 |
Impairment charges on intangible assets, net |  | – 768 |  | – 632 |  | – 141 |  | – 506 |  | – 5 |  |  |  | – 914 |  | – 1 138 |
Impairment charges and fair value changes on financial assets, net |  | 153 |  | 18 |  |  |  |  |  | 182 |  | 20 |  | 335 |  | 38 |
Additions to restructuring provisions |  | – 217 |  | – 229 |  | – 98 |  | – 165 |  | – 39 |  | – 98 |  | – 354 |  | – 492 |
Equity-based compensation of Novartis equity plans |  | – 714 |  | – 761 |  | – 64 |  | – 67 |  | – 180 |  | – 239 |  | – 958 |  | – 1 067 |
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2019 |  | 2018 |  | 2019 |  | 2018 |  | 2019 |  | 2018 |  | 2019 |  | 2018 |
Net sales to third parties from continuing operations |  | 37 714 |  | 34 892 |  | 9 731 |  | 9 859 |  |  |  |  |  | 47 445 |  | 44 751 |
Sales to continuing and discontinued segments |  | 783 |  | 741 |  | 141 |  | 177 |  | – 871 |  | – 836 |  | 53 |  | 82 |
Net sales from continuing operations |  | 38 497 |  | 35 633 |  | 9 872 |  | 10 036 |  | – 871 |  | – 836 |  | 47 498 |  | 44 833 |
Other revenues |  | 1 092 |  | 1 188 |  | 63 |  | 62 |  | 24 |  | 16 |  | 1 179 |  | 1 266 |
Cost of goods sold |  | – 10 050 |  | – 9 870 |  | – 5 334 |  | – 5 530 |  | 959 |  | 890 |  | – 14 425 |  | – 14 510 |
Gross profit from continuing operations |  | 29 539 |  | 26 951 |  | 4 601 |  | 4 568 |  | 112 |  | 70 |  | 34 252 |  | 31 589 |
Selling, general and administration |  | – 11 617 |  | – 10 907 |  | – 2 218 |  | – 2 305 |  | – 534 |  | – 505 |  | – 14 369 |  | – 13 717 |
Research and development |  | – 8 152 |  | – 7 675 |  | – 1 250 |  | – 814 |  |  |  |  |  | – 9 402 |  | – 8 489 |
Other income |  | 1 586 |  | 977 |  | 167 |  | 505 |  | 278 |  | 147 |  | 2 031 |  | 1 629 |
Other expense |  | – 2 069 |  | – 1 475 |  | – 749 |  | – 622 |  | – 608 |  | – 512 |  | – 3 426 |  | – 2 609 |
Operating income from continuing operations |  | 9 287 |  | 7 871 |  | 551 |  | 1 332 |  | – 752 |  | – 800 |  | 9 086 |  | 8 403 |
Income from associated companies |  | 1 |  | 1 |  | 2 |  | 5 |  | 656 |  | 6 432 |  | 659 |  | 6 438 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | – 850 |  | – 932 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 |  | 186 |
Income before taxes from continuing operations |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 940 |  | 14 095 |
Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | – 1 793 |  | – 1 295 |
Net income from continuing operations |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 147 |  | 12 800 |
Net loss from discontinued operations before gain on distribution of Alcon Inc. to Novartis AG shareholders |  |  |  |  |  |  |  |  |  |  |  |  |  | – 101 |  | – 186 |
Gain on distribution of Alcon Inc. to Novartis AG shareholders |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 691 |  |  |
Net income/(loss) from discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 590 |  | – 186 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 737 |  | 12 614 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 732 |  | 12 611 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  | 3 |
Included in net income from continuing operations are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 245 |  | 292 |
Depreciation of property, plant and equipment |  | – 952 |  | – 1 075 |  | – 283 |  | – 285 |  | – 110 |  | – 122 |  | – 1 345 |  | – 1 482 |
Depreciation of right-of-use assets 1 |  | – 247 |  |  |  | – 41 |  |  |  | – 17 |  |  |  | – 305 |  |  |
Amortization of intangible assets |  | – 2 509 |  | – 2 214 |  | – 315 |  | – 366 |  | – 12 |  | – 7 |  | – 2 836 |  | – 2 587 |
Impairment charges on property, plant and equipment, net |  | – 100 |  | – 239 |  | – 101 |  | – 60 |  | – 1 |  | – 2 |  | – 202 |  | – 301 |
Impairment charges on intangible assets, net |  | – 632 |  | – 592 |  | – 506 |  | – 249 |  |  |  |  |  | – 1 138 |  | – 841 |
Impairment charges and fair value changes on financial assets, net |  | 18 |  | 107 |  |  |  |  |  | 20 |  | – 113 |  | 38 |  | – 6 |
Additions to restructuring provisions |  | – 229 |  | – 395 |  | – 165 |  | – 32 |  | – 98 |  | – 94 |  | – 492 |  | – 521 |
Equity-based compensation of Novartis equity plans |  | – 761 |  | – 645 |  | – 67 |  | – 53 |  | – 239 |  | – 220 |  | – 1 067 |  | – 918 |
1 Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures.
Segmentation - Consolidated balance sheets | Segmentation – consolidated balance sheets
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |
Total assets |  | 83 112 |  | 71 225 |  | 16 825 |  | 16 468 |  | 32 122 |  | 30 677 |  | 132 059 |  | 118 370 |
Total liabilities |  | – 15 472 |  | – 15 332 |  | – 3 786 |  | – 3 804 |  | – 56 135 |  | – 43 683 |  | – 75 393 |  | – 62 819 |
Total equity |  |  |  |  |  |  |  |  |  |  |  |  |  | 56 666 |  | 55 551 |
Net debt 1 |  |  |  |  |  |  |  |  |  | 24 481 |  | 15 938 |  | 24 481 |  | 15 938 |
Net operating assets |  | 67 640 |  | 55 893 |  | 13 039 |  | 12 664 |  | 468 |  | 2 932 |  | 81 147 |  | 71 489 |
Included in assets and liabilities are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment |  | 9 863 |  | 9 632 |  | 1 849 |  | 1 888 |  | 551 |  | 549 |  | 12 263 |  | 12 069 |
Additions to property, plant and equipment 2 |  | 926 |  | 1 114 |  | 229 |  | 217 |  | 110 |  | 143 |  | 1 265 |  | 1 474 |
Total right-of-use assets |  | 1 489 |  | 1 487 |  | 133 |  | 136 |  | 54 |  | 54 |  | 1 676 |  | 1 677 |
Additions to right-of-use assets 2 |  | 264 |  | 454 |  | 67 |  | 49 |  | 15 |  | 34 |  | 346 |  | 537 |
Total goodwill and intangible assets |  | 56 839 |  | 46 336 |  | 9 817 |  | 8 892 |  | 152 |  | 83 |  | 66 808 |  | 55 311 |
Additions to goodwill and intangible assets 2 |  | 1 235 |  | 647 |  | 105 |  | 68 |  | 85 |  | 52 |  | 1 425 |  | 767 |
Total investment in associated companies |  | 194 |  | 128 |  | 8 |  | 7 |  | 9 430 |  | 8 509 |  | 9 632 |  | 8 644 |
Additions to investment in associated companies |  | 24 |  | 44 |  |  |  |  |  | 7 |  | 11 |  | 31 |  | 55 |
Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments |  |  |  |  |  |  |  |  |  | 11 563 |  | 11 446 |  | 11 563 |  | 11 446 |
Financial debts and derivative financial instruments |  |  |  |  |  |  |  |  |  | 36 044 |  | 27 384 |  | 36 044 |  | 27 384 |
Current income tax and deferred tax liabilities |  |  |  |  |  |  |  |  |  | 9 880 |  | 8 061 |  | 9 880 |  | 8 061 |
1 Note 29 provides additional disclosures related to net debt
2 Excluding the impact of business acquisitions
Net sales and total of selected non-current assets, by countries and regions |
|  | Net sales1 |  | Total of selected non-current assets2 |
(USD millions) |  | 2020 |  | % |  | 2019 |  | % |  | 2018 |  | % |  | 2020 |  | % |  | 2019 |  | % |
Country |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Switzerland |  | 800 |  | 2 |  | 848 |  | 2 |  | 795 |  | 2 |  | 34 904 |  | 39 |  | 33 032 |  | 43 |
United States |  | 16 484 |  | 34 |  | 16 280 |  | 34 |  | 14 618 |  | 33 |  | 39 889 |  | 44 |  | 28 893 |  | 37 |
France |  | 2 442 |  | 5 |  | 2 442 |  | 5 |  | 2 505 |  | 6 |  | 4 115 |  | 5 |  | 3 933 |  | 5 |
Germany |  | 4 518 |  | 9 |  | 4 120 |  | 9 |  | 3 972 |  | 9 |  | 2 607 |  | 3 |  | 2 554 |  | 3 |
Japan |  | 2 804 |  | 6 |  | 2 656 |  | 6 |  | 2 575 |  | 6 |  | 313 |  |  |  | 309 |  |  |
China |  | 2 573 |  | 5 |  | 2 214 |  | 5 |  | 1 953 |  | 4 |  | 714 |  | 1 |  | 684 |  | 1 |
Other |  | 19 038 |  | 39 |  | 18 885 |  | 39 |  | 18 333 |  | 40 |  | 7 837 |  | 8 |  | 8 296 |  | 11 |
Group |  | 48 659 |  | 100 |  | 47 445 |  | 100 |  | 44 751 |  | 100 |  | 90 379 |  | 100 |  | 77 701 |  | 100 |
Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 715 |  | 38 |  | 17 933 |  | 38 |  | 17 259 |  | 39 |  | 47 798 |  | 53 |  | 46 103 |  | 59 |
Americas |  | 19 725 |  | 41 |  | 19 713 |  | 41 |  | 18 032 |  | 39 |  | 40 391 |  | 45 |  | 29 389 |  | 38 |
Asia/Africa/Australasia |  | 10 219 |  | 21 |  | 9 799 |  | 21 |  | 9 460 |  | 22 |  | 2 190 |  | 2 |  | 2 209 |  | 3 |
Group |  | 48 659 |  | 100 |  | 47 445 |  | 100 |  | 44 751 |  | 100 |  | 90 379 |  | 100 |  | 77 701 |  | 100 |
1 Net sales to third party from continuing operations by location of customer
2 Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies
Net sales by region | Segmentation – Net sales by region 1
|  | 2020 USD m |  | 2019 USD m |  | Change (2019 to 2020) USD % |  | 2018 USD m |  | Change (2018 to 2019) USD % |
Innovative Medicines |  |  |  |  |  |  |  |  |  |  |
Europe |  | 13 484 |  | 12 818 |  | 5 |  | 12 296 |  | 4 |
US |  | 14 342 |  | 13 789 |  | 4 |  | 11 864 |  | 16 |
Asia/Africa/Australasia |  | 8 718 |  | 8 458 |  | 3 |  | 8 097 |  | 4 |
Canada and Latin America |  | 2 469 |  | 2 649 |  | – 7 |  | 2 635 |  | 1 |
Total |  | 39 013 |  | 37 714 |  | 3 |  | 34 892 |  | 8 |
Of which in Established Markets |  | 29 643 |  | 28 573 |  | 4 |  | 26 258 |  | 9 |
Of which in Emerging Growth Markets |  | 9 370 |  | 9 141 |  | 3 |  | 8 634 |  | 6 |
Sandoz |  |  |  |  |  |  |  |  |  |  |
Europe |  | 5 231 |  | 5 115 |  | 2 |  | 4 963 |  | 3 |
US |  | 2 142 |  | 2 491 |  | – 14 |  | 2 754 |  | – 10 |
Asia/Africa/Australasia |  | 1 501 |  | 1 341 |  | 12 |  | 1 363 |  | – 2 |
Canada and Latin America |  | 772 |  | 784 |  | – 2 |  | 779 |  | 1 |
Total |  | 9 646 |  | 9 731 |  | – 1 |  | 9 859 |  | – 1 |
Of which in Established Markets |  | 7 089 |  | 7 111 |  | 0 |  | 7 233 |  | – 2 |
Of which in Emerging Growth Markets |  | 2 557 |  | 2 620 |  | – 2 |  | 2 626 |  | 0 |
Group |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 715 |  | 17 933 |  | 4 |  | 17 259 |  | 4 |
US |  | 16 484 |  | 16 280 |  | 1 |  | 14 618 |  | 11 |
Asia/Africa/Australasia |  | 10 219 |  | 9 799 |  | 4 |  | 9 460 |  | 4 |
Canada and Latin America |  | 3 241 |  | 3 433 |  | – 6 |  | 3 414 |  | 1 |
Total |  | 48 659 |  | 47 445 |  | 3 |  | 44 751 |  | 6 |
Of which in Established Markets |  | 36 732 |  | 35 684 |  | 3 |  | 33 491 |  | 7 |
Of which in Emerging Growth Markets |  | 11 927 |  | 11 761 |  | 1 |  | 11 260 |  | 4 |
1 Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
Other revenue | Segmentation – other revenue
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019 |
Profit-sharing income |  | 835 |  | 732 |  |  |  | 2 |  |  |  |  |  | 835 |  | 734 |
Royalty income |  | 107 |  | 104 |  | 25 |  | 19 |  | 168 |  | 24 |  | 300 |  | 147 |
Milestone income |  | 39 |  | 201 |  | 11 |  | 30 |  |  |  |  |  | 50 |  | 231 |
Other 1 |  | 37 |  | 55 |  | 17 |  | 12 |  |  |  |  |  | 54 |  | 67 |
Total other revenues |  | 1 018 |  | 1 092 |  | 53 |  | 63 |  | 168 |  | 24 |  | 1 239 |  | 1 179 |
1 Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2019 |  | 2018 |  | 2019 |  | 2018 |  | 2019 |  | 2018 |  | 2019 |  | 2018 |
Profit-sharing income |  | 732 |  | 874 |  | 2 |  | 3 |  |  |  |  |  | 734 |  | 877 |
Royalty income |  | 104 |  | 162 |  | 19 |  | 10 |  | 24 |  | 16 |  | 147 |  | 188 |
Milestone income |  | 201 |  | 128 |  | 30 |  | 45 |  |  |  |  |  | 231 |  | 173 |
Other 1 |  | 55 |  | 24 |  | 12 |  | 4 |  |  |  |  |  | 67 |  | 28 |
Total other revenues |  | 1 092 |  | 1 188 |  | 63 |  | 62 |  | 24 |  | 16 |  | 1 179 |  | 1 266 |
1 Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.
Innovative Medicines |
Statement [line items] |
Net sales by business franchise | Innovative Medicines Division net sales by business franchise
|  | 2020 USD m |  | 2019 USD m |  | Change (2019 to 2020) USD % |  | 2018 USD m |  | Change (2018 to 2019) USD % |
Oncology |  |  |  |  |  |  |  |  |  |  |
Tasigna |  | 1 958 |  | 1 880 |  | 4 |  | 1 874 |  | 0 |
Promacta/Revolade |  | 1 738 |  | 1 416 |  | 23 |  | 1 174 |  | 21 |
Tafinlar + Mekinist |  | 1 542 |  | 1 338 |  | 15 |  | 1 155 |  | 16 |
Sandostatin |  | 1 439 |  | 1 585 |  | – 9 |  | 1 587 |  | 0 |
Jakavi |  | 1 339 |  | 1 114 |  | 20 |  | 977 |  | 14 |
Gleevec/Glivec |  | 1 188 |  | 1 263 |  | – 6 |  | 1 561 |  | – 19 |
Afinitor/Votubia |  | 1 083 |  | 1 539 |  | – 30 |  | 1 556 |  | – 1 |
Kisqali |  | 687 |  | 480 |  | 43 |  | 235 |  | 104 |
Exjade/Jadenu |  | 653 |  | 975 |  | – 33 |  | 1 099 |  | – 11 |
Votrient |  | 635 |  | 755 |  | – 16 |  | 828 |  | – 9 |
Kymriah |  | 474 |  | 278 |  | 71 |  | 76 |  | nm |
Lutathera |  | 445 |  | 441 |  | 1 |  | 167 |  | 164 |
Piqray |  | 320 |  | 116 |  | 176 |  |  |  | nm |
Adakveo |  | 105 |  | 1 |  | nm |  |  |  | nm |
Tabrecta |  | 35 |  |  |  | nm |  |  |  | nm |
Other |  | 1 070 |  | 1 189 |  | – 10 |  | 1 139 |  | 4 |
Total Novartis Oncology business unit |  | 14 711 |  | 14 370 |  | 2 |  | 13 428 |  | 7 |
Immunology, Hepatology and Dermatology |  |  |  |  |  |  |  |  |  |  |
Cosentyx |  | 3 995 |  | 3 551 |  | 13 |  | 2 837 |  | 25 |
Ilaris |  | 873 |  | 671 |  | 30 |  | 554 |  | 21 |
Other |  |  |  |  |  |  |  | 1 |  | nm |
Total Immunology, Hepatology and Dermatology |  | 4 868 |  | 4 222 |  | 15 |  | 3 392 |  | 24 |
Ophthalmology |  |  |  |  |  |  |  |  |  |  |
Lucentis |  | 1 933 |  | 2 086 |  | – 7 |  | 2 046 |  | 2 |
Xiidra |  | 376 |  | 192 |  | 96 |  |  |  | nm |
Beovu |  | 190 |  | 35 |  | nm |  |  |  | nm |
Other |  | 1 911 |  | 2 463 |  | – 22 |  | 1 995 |  | 23 |
Total Ophthalmology |  | 4 410 |  | 4 776 |  | – 8 |  | 4 558 |  | 5 |
Neuroscience |  |  |  |  |  |  |  |  |  |  |
Gilenya |  | 3 003 |  | 3 223 |  | – 7 |  | 3 341 |  | – 4 |
Zolgensma |  | 920 |  | 361 |  | 155 |  |  |  | nm |
Mayzent |  | 170 |  | 26 |  | nm |  |  |  | nm |
Aimovig |  | 164 |  | 103 |  | 59 |  | 8 |  | nm |
Kesimpta |  | 15 |  |  |  | nm |  |  |  | nm |
Other |  | 51 |  | 60 |  | – 15 |  | 80 |  | – 25 |
Total Neuroscience |  | 4 323 |  | 3 773 |  | 15 |  | 3 429 |  | 10 |
|  | 2020 USD m |  | 2019 USD m |  | Change (2019 to 2020) USD % |  | 2018 USD m |  | Change (2018 to 2019) USD % |
Cardiovascular, Renal and Metabolism |  |  |  |  |  |  |  |  |  |  |
Entresto |  | 2 497 |  | 1 726 |  | 45 |  | 1 028 |  | 68 |
Other |  | 1 |  | 24 |  | – 96 |  | 22 |  | 9 |
Total Cardiovascular, Renal and Metabolism |  | 2 498 |  | 1 750 |  | 43 |  | 1 050 |  | 67 |
Respiratory |  |  |  |  |  |  |  |  |  |  |
Xolair 1 |  | 1 251 |  | 1 173 |  | 7 |  | 1 039 |  | 13 |
Ultibro Group |  | 623 |  | 630 |  | – 1 |  | 703 |  | – 10 |
Other |  | 26 |  | 22 |  | 18 |  | 25 |  | – 12 |
Total Respiratory |  | 1 900 |  | 1 825 |  | 4 |  | 1 767 |  | 3 |
Established Medicines |  |  |  |  |  |  |  |  |  |  |
Galvus Group |  | 1 199 |  | 1 297 |  | – 8 |  | 1 284 |  | 1 |
Diovan Group |  | 1 003 |  | 1 064 |  | – 6 |  | 1 023 |  | 4 |
Exforge Group |  | 980 |  | 1 025 |  | – 4 |  | 1 002 |  | 2 |
Zortress/Certican |  | 452 |  | 485 |  | – 7 |  | 464 |  | 5 |
Neoral/Sandimmun(e) |  | 393 |  | 419 |  | – 6 |  | 463 |  | – 10 |
Voltaren/Cataflam |  | 360 |  | 417 |  | – 14 |  | 445 |  | – 6 |
Other |  | 1 916 |  | 2 291 |  | – 16 |  | 2 587 |  | – 11 |
Total Established Medicines |  | 6 303 |  | 6 998 |  | – 10 |  | 7 268 |  | – 4 |
Total Novartis Pharmaceuticals business unit |  | 24 302 |  | 23 344 |  | 4 |  | 21 464 |  | 9 |
Total division net sales |  | 39 013 |  | 37 714 |  | 3 |  | 34 892 |  | 8 |
1 Net sales reflect Xolair sales for all indications.
nm = not meaningful
Net sales of Top 20 products | Top 20 Innovative Medicines Division product net sales – 2020
Brands |  | Business franchise |  | Key indication |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology, Hepatology and Dermatology |  | Psoriasis, ankylosing spondylitis, psoriatic arthritis and non-radiographic axial spondyloarthritis |  | 2 516 |  | 1 479 |  | 3 995 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis |  | 1 562 |  | 1 441 |  | 3 003 |
Entresto |  | Cardiovascular, Renal and Metabolism |  | Chronic heart failure |  | 1 277 |  | 1 220 |  | 2 497 |
Tasigna |  | Oncology |  | Chronic myeloid leukemia |  | 859 |  | 1 099 |  | 1 958 |
Lucentis |  | Ophthalmology |  | Age-related macular degeneration |  |  |  | 1 933 |  | 1 933 |
Promacta/Revolade |  | Oncology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 833 |  | 905 |  | 1 738 |
Tafinlar + Mekinist |  | Oncology |  | BRAF V600+ metastatic and adjuvant melanoma; advanced non-small cell lung cancer (NSCLC) |  | 569 |  | 973 |  | 1 542 |
Sandostatin |  | Oncology |  | Carcinoid tumors and acromegaly |  | 837 |  | 602 |  | 1 439 |
Jakavi |  | Oncology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 339 |  | 1 339 |
Xolair 1 |  | Respiratory |  | Severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) and nasal polyps |  |  |  | 1 251 |  | 1 251 |
Galvus Group |  | Established Medicines |  | Type 2 diabetes |  |  |  | 1 199 |  | 1 199 |
Gleevec/Glivec |  | Oncology |  | Chronic myeloid leukemia and GIST |  | 315 |  | 873 |  | 1 188 |
Afinitor/Votubia |  | Oncology |  | Breast cancer/TSC |  | 644 |  | 439 |  | 1 083 |
Diovan Group |  | Established Medicines |  | Hypertension |  | 124 |  | 879 |  | 1 003 |
Exforge Group |  | Established Medicines |  | Hypertension |  | 16 |  | 964 |  | 980 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 459 |  | 461 |  | 920 |
Ilaris |  | Immunology, Hepatology and Dermatology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD and gout) |  | 400 |  | 473 |  | 873 |
Kisqali |  | Oncology |  | HR+/HER2- metastatic breast cancer |  | 318 |  | 369 |  | 687 |
Exjade/Jadenu |  | Oncology |  | Chronic iron overload |  | 138 |  | 515 |  | 653 |
Votrient |  | Oncology |  | Renal cell carcinoma |  | 259 |  | 376 |  | 635 |
Top 20 products total |  |  |  |  |  | 11 126 |  | 18 790 |  | 29 916 |
Rest of portfolio |  |  |  |  |  | 3 216 |  | 5 881 |  | 9 097 |
Total division sales |  |  |  |  |  | 14 342 |  | 24 671 |  | 39 013 |
1 Net sales reflect Xolair sales for all indications.
Top 20 Innovative Medicines Division product net sales – 2019
Brands |  | Business franchise |  | Key indication |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology, Hepatology and Dermatology |  | Psoriasis, ankylosing spondylitis and psoriatic arthritis |  | 2 220 |  | 1 331 |  | 3 551 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis |  | 1 736 |  | 1 487 |  | 3 223 |
Lucentis |  | Ophthalmology |  | Age-related macular degeneration |  |  |  | 2 086 |  | 2 086 |
Tasigna |  | Oncology |  | Chronic myeloid leukemia |  | 804 |  | 1 076 |  | 1 880 |
Entresto |  | Cardiovascular, Renal and Metabolism |  | Chronic heart failure |  | 925 |  | 801 |  | 1 726 |
Sandostatin |  | Oncology |  | Carcinoid tumors and acromegaly |  | 881 |  | 704 |  | 1 585 |
Afinitor/Votubia |  | Oncology |  | Breast cancer/TSC |  | 1 003 |  | 536 |  | 1 539 |
Promacta/Revolade |  | Oncology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 691 |  | 725 |  | 1 416 |
Tafinlar + Mekinist |  | Oncology |  | BRAF V600+ metastatic and adjuvant melanoma; advanced non-small cell lung cancer (NSCLC) |  | 481 |  | 857 |  | 1 338 |
Galvus Group |  | Established Medicines |  | Type 2 diabetes |  |  |  | 1 297 |  | 1 297 |
Gleevec/Glivec |  | Oncology |  | Chronic myeloid leukemia and GIST |  | 334 |  | 929 |  | 1 263 |
Xolair 1 |  | Respiratory |  | Severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) |  |  |  | 1 173 |  | 1 173 |
Jakavi |  | Oncology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 114 |  | 1 114 |
Diovan Group |  | Established Medicines |  | Hypertension |  | 86 |  | 978 |  | 1 064 |
Exforge Group |  | Established Medicines |  | Hypertension |  | 13 |  | 1 012 |  | 1 025 |
Exjade/Jadenu |  | Oncology |  | Chronic iron overload |  | 450 |  | 525 |  | 975 |
Votrient |  | Oncology |  | Renal cell carcinoma |  | 332 |  | 423 |  | 755 |
Ilaris |  | Immunology, Hepatology and Dermatology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD and gout) |  | 304 |  | 367 |  | 671 |
Zortress/Certican |  | Established Medicines |  | Transplantation |  | 169 |  | 316 |  | 485 |
Kisqali |  | Oncology |  | HR+/HER2- metastatic breast cancer |  | 250 |  | 230 |  | 480 |
Top 20 products total |  |  |  |  |  | 10 679 |  | 17 967 |  | 28 646 |
Rest of portfolio |  |  |  |  |  | 3 110 |  | 5 958 |  | 9 068 |
Total division sales |  |  |  |  |  | 13 789 |  | 23 925 |  | 37 714 |
1 Net sales reflect Xolair sales for all indications.
Top 20 Innovative Medicines Division product net sales – 2018
Brands |  | Business franchise |  | Key indication |  | US USD m |  | Rest of world USD m |  | Total USD m |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis |  | 1 765 |  | 1 576 |  | 3 341 |
Cosentyx |  | Immunology, Hepatology and Dermatology |  | Psoriasis, ankylosing spondylitis and psoriatic arthritis |  | 1 674 |  | 1 163 |  | 2 837 |
Lucentis |  | Ophthalmology |  | Age-related macular degeneration |  |  |  | 2 046 |  | 2 046 |
Tasigna |  | Oncology |  | Chronic myeloid leukemia |  | 806 |  | 1 068 |  | 1 874 |
Sandostatin |  | Oncology |  | Carcinoid tumors and acromegaly |  | 817 |  | 770 |  | 1 587 |
Gleevec/Glivec |  | Oncology |  | Chronic myeloid leukemia and GIST |  | 440 |  | 1 121 |  | 1 561 |
Afinitor/Votubia |  | Oncology |  | Breast cancer/TSC |  | 929 |  | 627 |  | 1 556 |
Galvus Group |  | Established Medicines |  | Type 2 diabetes |  |  |  | 1 284 |  | 1 284 |
Promacta/Revolade |  | Oncology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 581 |  | 593 |  | 1 174 |
Tafinlar + Mekinist |  | Oncology |  | BRAF V600+ metastatic and adjuvant melanoma; advanced non-small cell lung cancer (NSCLC) |  | 457 |  | 698 |  | 1 155 |
Exjade/Jadenu |  | Oncology |  | Chronic iron overload |  | 521 |  | 578 |  | 1 099 |
Xolair 1 |  | Respiratory |  | Severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) |  |  |  | 1 039 |  | 1 039 |
Entresto |  | Cardiovascular, Renal and Metabolism |  | Chronic heart failure |  | 556 |  | 472 |  | 1 028 |
Diovan Group |  | Established Medicines |  | Hypertension |  | 84 |  | 939 |  | 1 023 |
Exforge Group |  | Established Medicines |  | Hypertension |  | 19 |  | 983 |  | 1 002 |
Jakavi |  | Oncology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 977 |  | 977 |
Votrient |  | Oncology |  | Renal cell carcinoma |  | 404 |  | 424 |  | 828 |
Ilaris |  | Immunology, Hepatology and Dermatology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD and gout) |  | 262 |  | 292 |  | 554 |
Travoprost Group |  | Ophthalmology |  | Reduction of elevated intraocular pressure |  | 194 |  | 323 |  | 517 |
Zortress/Certican |  | Established Medicines |  | Transplantation |  | 145 |  | 319 |  | 464 |
Top 20 products total |  |  |  |  |  | 9 654 |  | 17 292 |  | 26 946 |
Rest of portfolio |  |  |  |  |  | 2 210 |  | 5 736 |  | 7 946 |
Total division sales |  |  |  |  |  | 11 864 |  | 23 028 |  | 34 892 |
1 Net sales reflect Xolair sales for all indications.
Sandoz [member] |
Statement [line items] |
Net sales by business franchise | Sandoz Division net sales by business franchise
|  | 2020 USD m |  | 2019 USD m |  | Change (2019 to 2020) USD % |  | 2018 USD m |  | Change (2018 to 2019) USD % |
Retail Generics 1 |  | 7 244 |  | 7 590 |  | – 5 |  | 7 880 |  | – 4 |
Biopharmaceuticals |  | 1 928 |  | 1 607 |  | 20 |  | 1 436 |  | 12 |
Anti-Infectives |  | 474 |  | 534 |  | – 11 |  | 543 |  | – 2 |
Total division net sales |  | 9 646 |  | 9 731 |  | – 1 |  | 9 859 |  | – 1 |
1 Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 23 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsNetSalesByBusinessFranchiseTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_StatementLineItems
Namespace Prefix: | nvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |